| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Radiological Diagnostics, German Cancer Research Center, D-69120 Heidelberg [H. H., M. V. K., I. Z., A. K., G. B., S. O. S., M. E., G. v. K.], and the Department of Obstetrics and Gynecology [P. G. K., W. W., U. S., C. W.] and the Institute of Physiology and Pathophysiology [P. V.], University of Mainz, D-55101 Mainz, Germany
Dynamic studies of Gd-based contrast agents in magnetic resonance imaging (MRI) are increasingly being used for tumor characterization as well as therapy response monitoring. Because detailed knowledge regarding the pathophysiological properties, which in turn are responsible for differences in contrast enhancement, remains fairly undetermined, it was the aim of this project to: (a) examine the relationship between contrast-enhanced dynamic MRI-derived characteristics and histological microvessel density counts, a recognized surrogate of tumor angiogenesis, from primary or recurrent cancers of the uterine cervix; and (b) correlate these parameters with lymphatic involvement to characterize tumor aggressiveness in terms of lymphatic spread.
Pharmacokinetic parameters (amplitude, A; exchange rate constant, k21) were calculated from a contrast-enhanced dynamic MRI series in 55 patients (ages 25–72 years; mean, 50 years) with biopsy-proven primary (n = 42) or recurrent (n = 13) uterine cervical cancer. Both pharmacokinetic parameters were correlated to histologically determined microvessel density counts (factor VIII-related antigen) and other pathological tumor characteristics obtained from the operative specimens after radical surgery. In addition, the magnetic resonance and histological data were correlated to the presence or absence of lymphatic system involvement.
Pharmacokinetic MRI-derived parameters (A and k21) increased with increasing histological microvessel density counts with r = 0.41 and 0.50, respectively. Lymphatic involvement was more comprehensibly assessed by the pharmacokinetic parameter k21 compared with histological microvessel density, resulting in a higher sensitivity, overall accuracy, and comparable specificity. Contrast-enhanced MRI parameters might prove to be applicable for estimation of tumor angiogenesis in uterine cervical cancer; thus, MRI may become an additional tool to characterize malignant progression in terms of lymphatic involvement in uterine cervical cancer.
1 To whom requests for reprints should be addressed, at Department of Radiological Diagnostics and Therapy, German Cancer Research Center (DKFZ). Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany. Phone: 49-6221-422525; Fax: 49-6221-422531.
Received 3/24/97. Accepted 8/22/97.
This article has been cited by other articles:
|
|
 |
|
  J. Hillengass, C. Zechmann, T. Bauerle, B. Wagner-Gund, C. Heiss, A. Benner, A. Ho, K. Neben, D. Hose, H.-U. Kauczor, et al. Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation Clin. Cancer Res., May 1, 2009; 15(9): 3118 - 3125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. T.-F. Shih, H.-A. Hou, C.-Y. Liu, B.-B. Chen, J.-L. Tang, H.-Y. Chen, S.-Y. Wei, M. Yao, S.-Y. Huang, W.-C. Chou, et al. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival Blood, April 2, 2009; 113(14): 3161 - 3167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Okuda, K. Oshio, H. Shinmoto, A. Tanimoto, H. Asada, T. Fujii, Y. Yoshimura, and S. Kuribayashi Semiquantitative Assessment of MR Imaging in Prediction of Efficacy of Gonadotropin-releasing Hormone Agonist for Volume Reduction of Uterine Leiomyoma: Initial Experience Radiology, September 1, 2008; 248(3): 917 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A RADJENOVIC, B J DALL, J P RIDGWAY, and M A SMITH Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI Br. J. Radiol., February 1, 2008; 81(962): 120 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hylton Dynamic Contrast-Enhanced Magnetic Resonance Imaging As an Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3293 - 3298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shimada, I. Ohashi, I. Kasahara, N. Miyasaka, and H. Shibuya Triple-Phase Dynamic MRI of Intratumoral Vessel Density and Hyalinization Grade in Uterine Leiomyomas Am. J. Roentgenol., April 1, 2004; 182(4): 1043 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A R Padhani MRI for assessing antivascular cancer treatments Br. J. Radiol., December 1, 2003; 76(suppl_1): S60 - S80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Morgan, A. L. Thomas, J. Drevs, J. Hennig, M. Buchert, A. Jivan, M. A. Horsfield, K. Mross, H. A. Ball, L. Lee, et al. Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies J. Clin. Oncol., November 1, 2003; 21(21): 3955 - 3964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Okamoto, Y. O. Tanaka, M. Nishida, H. Tsunoda, H. Yoshikawa, and Y. Itai MR Imaging of the Uterine Cervix: Imaging-Pathologic Correlation RadioGraphics, March 1, 2003; 23(2): 425 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hawighorst, S. Postema, and P. M. T. Pattynama Dynamic MR Imaging in Cervical Carcinoma • Drs Postema and Pattynama respond: Radiology, October 1, 1999; 213(2): 617 - 618. [Full Text]
|
|
|
|
|
|
S. Postema, P. M. T. Pattynama, C. S. P. van Rijswijk, and J. B. Trimbos Cervical Carcinoma: Can Dynamic Contrast-enhanced MR Imaging Help Predict Tumor Aggressiveness? Radiology, January 1, 1999; 210(1): 217 - 220. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
